Chemclin Diagnostics Co. Ltd. A (SHG:688468) — Market Cap & Net Worth
Market Cap & Net Worth: Chemclin Diagnostics Co. Ltd. A (688468)
Chemclin Diagnostics Co. Ltd. A (SHG:688468) has a market capitalization of $392.67 Million (CN¥2.68 Billion) as of October 10, 2026. Listed on the SHG stock exchange, this China-based company holds position #13601 globally and #4099 in its home market, demonstrating a 1.52% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chemclin Diagnostics Co. Ltd. A's stock price CN¥6.69 by its total outstanding shares 401108000 (401.11 Million).
Chemclin Diagnostics Co. Ltd. A Market Cap History: 2021 to 2026
Chemclin Diagnostics Co. Ltd. A's market capitalization history from 2021 to 2026. Data shows change from $987.99 Million to $392.67 Million (-20.36% CAGR). Check Chemclin Diagnostics Co. Ltd. A (688468) stock price for real-time trading data and today's change.
Chemclin Diagnostics Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chemclin Diagnostics Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see 688468 cash flow metrics for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
1.30x
Chemclin Diagnostics Co. Ltd. A's market cap is 1.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
9.70x
Chemclin Diagnostics Co. Ltd. A's market cap is 9.70 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $987.99 Million | $470.77 Million | $142.76 Million | 2.10x | 6.92x |
| 2022 | $529.16 Million | $465.27 Million | $152.63 Million | 1.14x | 3.47x |
| 2023 | $621.61 Million | $445.34 Million | $147.37 Million | 1.40x | 4.22x |
| 2024 | $402.06 Million | $436.29 Million | $127.07 Million | 0.92x | 3.16x |
| 2025 | $430.82 Million | $332.68 Million | $44.41 Million | 1.30x | 9.70x |
Competitor Companies of 688468 by Market Capitalization
Companies near Chemclin Diagnostics Co. Ltd. A in the global market cap rankings as of October 10, 2026. See 688468 net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to Chemclin Diagnostics Co. Ltd. A by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #88 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #155 globally with a market cap of $155.26 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #477 globally with a market cap of $57.11 Billion USD ( CN¥390.28 Billion CNY).
- Natera Inc (NASDAQ:NTRA): Ranked #580 globally with a market cap of $47.01 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #88 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $658.02 |
| #155 | Danaher Corporation | NYSE:DHR | $155.26 Billion | $219.81 |
| #477 | WuXi AppTec Co Ltd | SHG:603259 | $57.11 Billion | CN¥157.80 |
| #580 | Natera Inc | NASDAQ:NTRA | $47.01 Billion | $400.71 |
Chemclin Diagnostics Co. Ltd. A Historical Marketcap From 2021 to 2026
Between 2021 and today, Chemclin Diagnostics Co. Ltd. A's market cap moved from $987.99 Million to $ 392.67 Million, with a yearly change of -20.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥392.67 Million | -8.86% |
| 2025 | CN¥430.82 Million | +7.15% |
| 2024 | CN¥402.06 Million | -35.32% |
| 2023 | CN¥621.61 Million | +17.47% |
| 2022 | CN¥529.16 Million | -46.44% |
| 2021 | CN¥987.99 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 10th, 2026 the market cap of Chemclin Diagnostics Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $392.67 Million USD |
| MoneyControl | $392.67 Million USD |
| MarketWatch | $392.67 Million USD |
| marketcap.company | $392.67 Million USD |
| Reuters | $392.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Chemclin Diagnostics Co. Ltd. A
Chemclin Diagnostics Co., Ltd. engages in the research and development, production, and sale of clinical immune chemiluminescence diagnostic reagents and instruments. Its products include LiCAA series of diagnostic reagents based on photo-induced chemiluminescence and CC series based on enzymatic chemiluminescence diagnostic reagents and instruments, primarily used for infectious diseases, such a… Read more